Roche/Genentech Herceptin Trials Aim To Reduce Cardiotoxicity
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Roche and Genentech are conducting trials focusing on reducing the risk of cardiotoxicity associated with the companies’ breast cancer therapy Herceptin (trastuzumab).